secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001846253-23-000093
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck
--------------------------------------------------------------------------------

- Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.
- H1 revenue $23.9M (vs $16.8M) driven by $10M milestone from TECVAYLI first commercial sale in EU.
- Added 4 new partners: Merck, Neurocrine, Stanford, Seattle Children's; total active programs 305.
- Batoclimab BLA accepted in China for gMG; IMVT-1402 Phase 1 initiated; GSK milestone $2.0M earned.
- Cash and equivalents $103.1M; expects year-end cash slightly higher than 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/0001846253-23-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/lgnd-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001846253-23-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer